Fosamprenavir Expanded Access

An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00240552

Enrollment

Registered

2005-10-18

Start date

2003-07-31

Completion date

2005-08-31

Last updated

2016-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Human Immunodeficiency Virus

Keywords

protease inhibitor, Treatment Experienced, amprenavir, fosamprenavir, GW433908, HIV, pro drug

Brief summary

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

Interventions

DRUGfosamprenavir

DRUGTelzir®

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HIV-1 infected subjects. * Subjects must belong to one of the following populations: 1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs. 2. Subjects who already receive amprenavir (Agenerase®) 3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026